 Kenneth Malcolm
Concepts (313)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium abscessus | 11 | 2025 | 113 | 4.170 |
Why?
| | Mycobacterium Infections, Nontuberculous | 16 | 2025 | 360 | 3.210 |
Why?
| | Neutrophils | 30 | 2025 | 1238 | 2.820 |
Why?
| | Host-Pathogen Interactions | 4 | 2025 | 367 | 1.810 |
Why?
| | Cystic Fibrosis | 16 | 2025 | 1105 | 1.720 |
Why?
| | Phagocytosis | 7 | 2025 | 379 | 1.080 |
Why?
| | Azithromycin | 4 | 2020 | 94 | 0.890 |
Why?
| | Immunity, Humoral | 1 | 2025 | 118 | 0.880 |
Why?
| | Interferons | 2 | 2016 | 199 | 0.790 |
Why?
| | Lipopolysaccharides | 11 | 2025 | 886 | 0.770 |
Why?
| | Gene Expression Regulation | 7 | 2020 | 2615 | 0.710 |
Why?
| | Immunity, Innate | 3 | 2025 | 832 | 0.660 |
Why?
| | Klebsiella pneumoniae | 2 | 2018 | 47 | 0.620 |
Why?
| | Pseudomonas | 1 | 2018 | 31 | 0.610 |
Why?
| | Pseudomonas aeruginosa | 8 | 2022 | 353 | 0.580 |
Why?
| | Fomites | 1 | 2017 | 7 | 0.560 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2018 | 225 | 0.560 |
Why?
| | Nontuberculous Mycobacteria | 7 | 2025 | 204 | 0.550 |
Why?
| | Anti-Bacterial Agents | 11 | 2024 | 1800 | 0.530 |
Why?
| | Mitogen-Activated Protein Kinases | 7 | 2004 | 316 | 0.410 |
Why?
| | Pseudomonas Infections | 5 | 2022 | 224 | 0.410 |
Why?
| | Neutrophil Activation | 1 | 2013 | 81 | 0.400 |
Why?
| | Mycobacterium Infections | 1 | 2013 | 63 | 0.390 |
Why?
| | Reactive Oxygen Species | 4 | 2020 | 619 | 0.390 |
Why?
| | Staphylococcus aureus | 3 | 2015 | 452 | 0.370 |
Why?
| | Mycobacterium | 1 | 2013 | 109 | 0.370 |
Why?
| | Superoxides | 5 | 2018 | 202 | 0.360 |
Why?
| | Bacteria | 1 | 2018 | 858 | 0.350 |
Why?
| | Sputum | 5 | 2025 | 311 | 0.340 |
Why?
| | Microbial Viability | 3 | 2018 | 91 | 0.310 |
Why?
| | Immunoglobulin G | 2 | 2025 | 886 | 0.310 |
Why?
| | Biofilms | 5 | 2014 | 262 | 0.290 |
Why?
| | Extracellular Traps | 2 | 2018 | 53 | 0.280 |
Why?
| | Interleukin-8 | 3 | 2020 | 269 | 0.260 |
Why?
| | Immunoglobulin M | 2 | 2025 | 288 | 0.250 |
Why?
| | Humans | 45 | 2025 | 137514 | 0.250 |
Why?
| | Mannose-Binding Lectin | 1 | 2025 | 23 | 0.240 |
Why?
| | Phage Therapy | 1 | 2025 | 15 | 0.240 |
Why?
| | Extracellular Space | 2 | 2018 | 121 | 0.230 |
Why?
| | Gene Expression Profiling | 3 | 2018 | 1770 | 0.230 |
Why?
| | Cell Separation | 3 | 2016 | 320 | 0.220 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2002 | 765 | 0.220 |
Why?
| | Antibodies, Bacterial | 1 | 2025 | 146 | 0.220 |
Why?
| | Complement C3 | 1 | 2025 | 210 | 0.220 |
Why?
| | Tobramycin | 4 | 2016 | 51 | 0.200 |
Why?
| | Toll-Like Receptors | 3 | 2017 | 186 | 0.200 |
Why?
| | GTP-Binding Proteins | 1 | 2003 | 163 | 0.190 |
Why?
| | Cytokines | 8 | 2018 | 2095 | 0.190 |
Why?
| | Antimalarials | 1 | 2022 | 32 | 0.190 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 7 | 2011 | 283 | 0.190 |
Why?
| | Primary Cell Culture | 2 | 2020 | 172 | 0.190 |
Why?
| | Myelodysplastic Syndromes | 1 | 2023 | 135 | 0.190 |
Why?
| | Complement Activation | 1 | 2025 | 412 | 0.180 |
Why?
| | Case-Control Studies | 3 | 2020 | 3546 | 0.180 |
Why?
| | Pneumonia, Bacterial | 3 | 2013 | 117 | 0.180 |
Why?
| | Bacteriophages | 1 | 2022 | 95 | 0.170 |
Why?
| | Chemokine CCL4 | 1 | 2020 | 23 | 0.170 |
Why?
| | RNA Splicing | 2 | 2023 | 268 | 0.170 |
Why?
| | Chloroquine | 1 | 2020 | 52 | 0.170 |
Why?
| | Mycobacterium tuberculosis | 1 | 2022 | 317 | 0.160 |
Why?
| | Disease Models, Animal | 5 | 2024 | 4295 | 0.150 |
Why?
| | Sirolimus | 1 | 2020 | 275 | 0.150 |
Why?
| | Intracellular Space | 1 | 2018 | 69 | 0.140 |
Why?
| | Autophagy | 1 | 2020 | 282 | 0.140 |
Why?
| | Lung | 9 | 2024 | 4066 | 0.140 |
Why?
| | Respiratory System | 1 | 2018 | 158 | 0.140 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 429 | 0.140 |
Why?
| | Aztreonam | 1 | 2016 | 10 | 0.130 |
Why?
| | Antiviral Agents | 1 | 2003 | 740 | 0.130 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2023 | 620 | 0.130 |
Why?
| | Signal Transduction | 3 | 2020 | 5096 | 0.130 |
Why?
| | Survival Analysis | 2 | 2016 | 1320 | 0.120 |
Why?
| | C-Reactive Protein | 1 | 2018 | 411 | 0.120 |
Why?
| | Mice | 14 | 2024 | 17843 | 0.120 |
Why?
| | Alternative Splicing | 1 | 2017 | 227 | 0.120 |
Why?
| | Interferon-alpha | 1 | 2016 | 198 | 0.120 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 891 | 0.120 |
Why?
| | Microbial Sensitivity Tests | 4 | 2022 | 362 | 0.120 |
Why?
| | Severity of Illness Index | 4 | 2018 | 2838 | 0.110 |
Why?
| | Antimicrobial Cationic Peptides | 1 | 2015 | 81 | 0.110 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2014 | 55 | 0.110 |
Why?
| | Cell Movement | 4 | 2013 | 972 | 0.110 |
Why?
| | Leukocytes, Mononuclear | 1 | 2017 | 558 | 0.110 |
Why?
| | Metalloproteases | 1 | 2014 | 43 | 0.110 |
Why?
| | RNA, Messenger | 3 | 2022 | 2838 | 0.110 |
Why?
| | Oxidants | 1 | 2014 | 110 | 0.110 |
Why?
| | Deoxyribonucleases | 2 | 2011 | 24 | 0.110 |
Why?
| | Phagocytes | 1 | 2014 | 100 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 892 | 0.110 |
Why?
| | Thiazolidinediones | 1 | 2014 | 137 | 0.110 |
Why?
| | Quorum Sensing | 1 | 2014 | 78 | 0.110 |
Why?
| | Odds Ratio | 1 | 2016 | 1063 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2011 | 1242 | 0.100 |
Why?
| | Cell Death | 2 | 2013 | 370 | 0.100 |
Why?
| | Rhinitis | 1 | 2015 | 158 | 0.100 |
Why?
| | Virulence Factors | 1 | 2014 | 167 | 0.100 |
Why?
| | Wound Infection | 1 | 2013 | 33 | 0.100 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1524 | 0.100 |
Why?
| | Prospective Studies | 5 | 2025 | 7598 | 0.100 |
Why?
| | Sinusitis | 1 | 2015 | 221 | 0.100 |
Why?
| | Male | 13 | 2025 | 67718 | 0.090 |
Why?
| | Cellular Structures | 1 | 2011 | 5 | 0.090 |
Why?
| | Lipid Metabolism | 1 | 2015 | 511 | 0.090 |
Why?
| | Contact Lenses, Hydrophilic | 1 | 2011 | 7 | 0.090 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 277 | 0.090 |
Why?
| | Animals | 15 | 2024 | 37011 | 0.090 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2013 | 242 | 0.090 |
Why?
| | Macrophages | 4 | 2023 | 1548 | 0.090 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2013 | 260 | 0.090 |
Why?
| | Neutrophil Infiltration | 3 | 2013 | 107 | 0.090 |
Why?
| | Actins | 3 | 2009 | 416 | 0.090 |
Why?
| | Cell Lineage | 1 | 2013 | 346 | 0.090 |
Why?
| | Chemokine CXCL5 | 1 | 2011 | 11 | 0.090 |
Why?
| | Eye Infections, Bacterial | 1 | 2011 | 28 | 0.090 |
Why?
| | Treatment Outcome | 4 | 2025 | 10821 | 0.090 |
Why?
| | Lipids | 1 | 2015 | 664 | 0.090 |
Why?
| | Interleukin-17 | 1 | 2011 | 120 | 0.080 |
Why?
| | Viruses | 1 | 2011 | 112 | 0.080 |
Why?
| | Biomarkers | 4 | 2025 | 4172 | 0.080 |
Why?
| | Species Specificity | 1 | 2011 | 593 | 0.080 |
Why?
| | Female | 12 | 2025 | 73162 | 0.080 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2013 | 531 | 0.080 |
Why?
| | Retroviridae | 1 | 2008 | 99 | 0.070 |
Why?
| | Burns | 1 | 2013 | 323 | 0.070 |
Why?
| | cdc42 GTP-Binding Protein | 2 | 2006 | 22 | 0.070 |
Why?
| | Mitochondria | 1 | 2014 | 947 | 0.070 |
Why?
| | Pulmonary Alveoli | 1 | 2011 | 405 | 0.070 |
Why?
| | Peptides | 2 | 2011 | 986 | 0.070 |
Why?
| | Transgenes | 1 | 2008 | 180 | 0.070 |
Why?
| | Adult | 8 | 2025 | 37821 | 0.070 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2008 | 66 | 0.070 |
Why?
| | Pulmonary Artery | 1 | 2013 | 1083 | 0.070 |
Why?
| | Bone Marrow | 1 | 2008 | 286 | 0.070 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2007 | 45 | 0.070 |
Why?
| | Endothelium, Vascular | 1 | 2013 | 923 | 0.070 |
Why?
| | Membrane Glycoproteins | 2 | 2014 | 501 | 0.070 |
Why?
| | Escherichia coli Infections | 1 | 2007 | 111 | 0.060 |
Why?
| | Middle Aged | 4 | 2020 | 33355 | 0.060 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2006 | 87 | 0.060 |
Why?
| | Cohort Studies | 2 | 2020 | 5730 | 0.060 |
Why?
| | Cell Culture Techniques | 1 | 2008 | 363 | 0.060 |
Why?
| | Up-Regulation | 3 | 2006 | 846 | 0.060 |
Why?
| | Inflammation | 5 | 2022 | 2837 | 0.060 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2005 | 43 | 0.060 |
Why?
| | Respiratory Mucosa | 1 | 2008 | 324 | 0.060 |
Why?
| | Toll-Like Receptor 4 | 2 | 2007 | 274 | 0.060 |
Why?
| | MAP Kinase Signaling System | 1 | 2007 | 322 | 0.060 |
Why?
| | Dinoprostone | 1 | 2005 | 191 | 0.060 |
Why?
| | DNA | 2 | 2009 | 1460 | 0.060 |
Why?
| | Membrane Microdomains | 1 | 2004 | 33 | 0.060 |
Why?
| | Transcription, Genetic | 4 | 2008 | 1458 | 0.060 |
Why?
| | Drug Therapy, Combination | 3 | 2013 | 1060 | 0.060 |
Why?
| | beta-Cyclodextrins | 1 | 2004 | 30 | 0.060 |
Why?
| | Inflammation Mediators | 2 | 2011 | 514 | 0.060 |
Why?
| | Enzyme Precursors | 1 | 2003 | 15 | 0.050 |
Why?
| | Chemokines, CXC | 1 | 2004 | 70 | 0.050 |
Why?
| | NF-kappa B | 4 | 2013 | 694 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 308 | 0.050 |
Why?
| | Receptors, CXCR4 | 1 | 2004 | 85 | 0.050 |
Why?
| | Splicing Factor U2AF | 1 | 2023 | 16 | 0.050 |
Why?
| | Zymosan | 1 | 2023 | 65 | 0.050 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2024 | 184 | 0.050 |
Why?
| | Young Adult | 3 | 2020 | 13243 | 0.050 |
Why?
| | Myxovirus Resistance Proteins | 1 | 2003 | 13 | 0.050 |
Why?
| | Mycobacterium avium | 1 | 2023 | 21 | 0.050 |
Why?
| | Bacterial Load | 2 | 2015 | 68 | 0.050 |
Why?
| | eIF-2 Kinase | 1 | 2003 | 31 | 0.050 |
Why?
| | Chemotaxis | 1 | 2023 | 131 | 0.050 |
Why?
| | STAT1 Transcription Factor | 1 | 2003 | 75 | 0.050 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2002 | 350 | 0.050 |
Why?
| | Escherichia coli | 1 | 2007 | 815 | 0.050 |
Why?
| | Enzyme Activation | 4 | 2008 | 816 | 0.050 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2002 | 67 | 0.050 |
Why?
| | Toll-Like Receptor 2 | 1 | 2003 | 117 | 0.050 |
Why?
| | Macrophages, Alveolar | 1 | 2005 | 392 | 0.050 |
Why?
| | Risk Factors | 1 | 2016 | 10356 | 0.050 |
Why?
| | Interferon Type I | 1 | 2003 | 142 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2003 | 366 | 0.050 |
Why?
| | Gene Expression | 2 | 2008 | 1505 | 0.050 |
Why?
| | Ciprofloxacin | 2 | 2013 | 30 | 0.040 |
Why?
| | STAT3 Transcription Factor | 1 | 2003 | 208 | 0.040 |
Why?
| | Transcriptional Activation | 2 | 2013 | 379 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2002 | 285 | 0.040 |
Why?
| | Receptors, Cell Surface | 1 | 2003 | 391 | 0.040 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2003 | 434 | 0.040 |
Why?
| | Trans-Activators | 1 | 2003 | 399 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2022 | 683 | 0.040 |
Why?
| | Apoptosis | 2 | 2008 | 2557 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2025 | 1047 | 0.040 |
Why?
| | Glycolipids | 1 | 2020 | 42 | 0.040 |
Why?
| | Mice, Knockout | 3 | 2014 | 3020 | 0.040 |
Why?
| | Complement System Proteins | 1 | 2023 | 328 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2011 | 7593 | 0.040 |
Why?
| | Transforming Growth Factor beta | 1 | 2002 | 480 | 0.040 |
Why?
| | Time Factors | 3 | 2018 | 6817 | 0.040 |
Why?
| | British Columbia | 1 | 2018 | 21 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2015 | 654 | 0.040 |
Why?
| | Chemokine CXCL1 | 2 | 2011 | 76 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2023 | 2182 | 0.040 |
Why?
| | Cell Migration Inhibition | 2 | 2011 | 17 | 0.030 |
Why?
| | Chemotaxis, Leukocyte | 2 | 2011 | 138 | 0.030 |
Why?
| | Morbidity | 1 | 2018 | 322 | 0.030 |
Why?
| | Drug Administration Routes | 1 | 2016 | 38 | 0.030 |
Why?
| | Imidazoles | 3 | 2002 | 244 | 0.030 |
Why?
| | RNA Precursors | 1 | 2017 | 153 | 0.030 |
Why?
| | Mice, Inbred C57BL | 4 | 2011 | 5792 | 0.030 |
Why?
| | Proteins | 1 | 2002 | 1012 | 0.030 |
Why?
| | Aged | 2 | 2015 | 23798 | 0.030 |
Why?
| | Cathelicidins | 1 | 2015 | 41 | 0.030 |
Why?
| | Drug Interactions | 1 | 2016 | 409 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2003 | 1507 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2016 | 221 | 0.030 |
Why?
| | NADPH Oxidase 2 | 1 | 2014 | 39 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1703 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2039 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2016 | 596 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2002 | 3292 | 0.030 |
Why?
| | Gentamicins | 1 | 2015 | 54 | 0.030 |
Why?
| | Enzyme Inhibitors | 3 | 2002 | 845 | 0.030 |
Why?
| | Chronic Disease | 2 | 2015 | 1790 | 0.030 |
Why?
| | NADPH Oxidases | 1 | 2014 | 110 | 0.030 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2014 | 79 | 0.030 |
Why?
| | Drug Resistance, Bacterial | 1 | 2015 | 183 | 0.030 |
Why?
| | Recombinant Proteins | 2 | 2011 | 1357 | 0.030 |
Why?
| | PPAR gamma | 1 | 2014 | 183 | 0.030 |
Why?
| | Survival Rate | 1 | 2018 | 1980 | 0.030 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 2 | 2003 | 163 | 0.020 |
Why?
| | Spleen | 1 | 2015 | 516 | 0.020 |
Why?
| | Chemokine CCL2 | 2 | 2003 | 117 | 0.020 |
Why?
| | Adenoviridae | 1 | 2013 | 193 | 0.020 |
Why?
| | Fibrinogen | 1 | 2013 | 170 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2013 | 331 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2013 | 227 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2013 | 329 | 0.020 |
Why?
| | Drug Synergism | 1 | 2013 | 379 | 0.020 |
Why?
| | Mutation | 1 | 2023 | 3964 | 0.020 |
Why?
| | Neovascularization, Physiologic | 1 | 2013 | 177 | 0.020 |
Why?
| | Down-Regulation | 2 | 2006 | 658 | 0.020 |
Why?
| | Asthma | 1 | 2005 | 2290 | 0.020 |
Why?
| | Monocytes | 1 | 2014 | 568 | 0.020 |
Why?
| | Suspensions | 1 | 2011 | 37 | 0.020 |
Why?
| | Gene Deletion | 1 | 2013 | 393 | 0.020 |
Why?
| | Chemokine CXCL2 | 1 | 2011 | 43 | 0.020 |
Why?
| | Corneal Ulcer | 1 | 2011 | 16 | 0.020 |
Why?
| | Epithelium, Corneal | 1 | 2011 | 41 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 621 | 0.020 |
Why?
| | Genome | 1 | 2013 | 292 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2003 | 974 | 0.020 |
Why?
| | Bacterial Adhesion | 1 | 2011 | 99 | 0.020 |
Why?
| | Methacrylates | 1 | 2011 | 116 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2755 | 0.020 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 256 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2011 | 467 | 0.020 |
Why?
| | Rabbits | 1 | 2011 | 792 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4031 | 0.020 |
Why?
| | Cell Line | 2 | 2008 | 2852 | 0.020 |
Why?
| | Granulocytes | 1 | 2008 | 80 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2018 | 5139 | 0.020 |
Why?
| | Pyridines | 2 | 2002 | 508 | 0.020 |
Why?
| | Enzyme Induction | 1 | 2008 | 90 | 0.020 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2011 | 327 | 0.020 |
Why?
| | Colorado | 1 | 2018 | 4521 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2013 | 914 | 0.020 |
Why?
| | Acute Lung Injury | 1 | 2011 | 288 | 0.020 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2008 | 173 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 234 | 0.020 |
Why?
| | Toll-Like Receptor 3 | 1 | 2007 | 28 | 0.020 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2006 | 54 | 0.020 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2007 | 134 | 0.020 |
Why?
| | I-kappa B Proteins | 1 | 2006 | 81 | 0.020 |
Why?
| | Keratinocytes | 1 | 2007 | 248 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2013 | 2482 | 0.020 |
Why?
| | Jurkat Cells | 1 | 2005 | 134 | 0.010 |
Why?
| | Child | 2 | 2020 | 22037 | 0.010 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 152 | 0.010 |
Why?
| | Cyclodextrins | 1 | 2004 | 8 | 0.010 |
Why?
| | rac GTP-Binding Proteins | 1 | 2004 | 32 | 0.010 |
Why?
| | Vital Capacity | 1 | 2005 | 309 | 0.010 |
Why?
| | Receptors, Interleukin-8B | 1 | 2004 | 26 | 0.010 |
Why?
| | Syk Kinase | 1 | 2003 | 21 | 0.010 |
Why?
| | Anthracenes | 1 | 2003 | 31 | 0.010 |
Why?
| | Chemokine CXCL12 | 1 | 2004 | 80 | 0.010 |
Why?
| | rho GTP-Binding Proteins | 1 | 2004 | 61 | 0.010 |
Why?
| | Forced Expiratory Volume | 1 | 2005 | 532 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2015 | 5427 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2008 | 1255 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2011 | 4206 | 0.010 |
Why?
| | Chemokines | 1 | 2004 | 229 | 0.010 |
Why?
| | Dexamethasone | 1 | 2005 | 377 | 0.010 |
Why?
| | Bone Marrow Cells | 1 | 2004 | 313 | 0.010 |
Why?
| | DNA Primers | 1 | 2003 | 514 | 0.010 |
Why?
| | Precipitin Tests | 1 | 2002 | 100 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2005 | 1324 | 0.010 |
Why?
| | Protein Phosphatase 2 | 1 | 2002 | 41 | 0.010 |
Why?
| | Cholesterol | 1 | 2004 | 413 | 0.010 |
Why?
| | Intubation, Gastrointestinal | 1 | 2002 | 77 | 0.010 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2002 | 114 | 0.010 |
Why?
| | Aminopyridines | 1 | 2002 | 101 | 0.010 |
Why?
| | Cell Survival | 1 | 2005 | 1122 | 0.010 |
Why?
| | Ligands | 1 | 2004 | 665 | 0.010 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2002 | 144 | 0.010 |
Why?
| | Transcription Factor AP-1 | 1 | 2002 | 92 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 2005 | 498 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2008 | 1099 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2008 | 1979 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 21555 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2003 | 455 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2002 | 784 | 0.010 |
Why?
| | Homeostasis | 1 | 2004 | 622 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1108 | 0.010 |
Why?
| | Base Sequence | 1 | 2003 | 2180 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2146 | 0.010 |
Why?
| | Proteome | 1 | 2002 | 474 | 0.010 |
Why?
|
|
Malcolm's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|